Rosa Maria Pascale

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1250665/publications.pdf

Version: 2024-02-01

77 papers	3,143 citations	147801 31 h-index	168389 53 g-index
77 all docs	77 docs citations	77 times ranked	4424 citing authors

#	Article	IF	Citations
1	The Warburg Effect 97 Years after Its Discovery. Cancers, 2020, 12, 2819.	3.7	153
2	Cholesterol biosynthesis supports the growth of hepatocarcinoma lesions depleted of fatty acid synthase in mice and humans. Gut, 2020, 69, 177-186.	12.1	121
3	A functional mammalian target of rapamycin complex 1 signaling is indispensable for câ€Mycâ€driven hepatocarcinogenesis. Hepatology, 2017, 66, 167-181.	7.3	119
4	Pleiotropic effects of methionine adenosyltransferases deregulation as determinants of liver cancer progression and prognosis. Journal of Hepatology, 2013, 59, 830-841.	3.7	117
5	Inactivation of fatty acid synthase impairs hepatocarcinogenesis driven by AKT in mice and humans. Journal of Hepatology, 2016, 64, 333-341.	3.7	115
6	Connective tissue growth factor autocriny in human hepatocellular carcinoma: Oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation. Hepatology, 2011, 54, 2149-2158.	7.3	108
7	Dual-Specificity Phosphatase 1 Ubiquitination in Extracellular Signal-Regulated Kinaseâ€“Mediated Control of Growth in Human Hepatocellular Carcinoma. Cancer Research, 2008, 68, 4192-4200.	0.9	107
8	Chemoprevention of hepatocarcinogenesis. Alcohol, 2002, 27, 193-198.	1.7	95
9	SKP2 and CKS1 Promote Degradation of Cell Cycle Regulators and Are Associated With Hepatocellular Carcinoma Prognosis. Gastroenterology, 2009, 137, 1816-1826.e10.	1.3	95
10	5â€²-Methylthioadenosine administration prevents lipid peroxidation and fibrogenesis induced in rat liver by carbon-tetrachloride intoxication. Journal of Hepatology, 2001, 34, 386-394.	3.7	93
11	Role of HSP90, CDC37, and CRM1 as modulators of P16INK4Aactivity in rat liver carcinogenesis and human liver cancer. Hepatology, 2005, 42, 1310-1319.	7.3	87
12	Stearoyl-CoA desaturase 1 (Scd1) gene overexpression is associated with genetic predisposition to hepatocarcinogenesis in mice and rats. Carcinogenesis, 2002, 23, 1933-1936.	2.8	81
13	Pan-mTOR inhibitor MLN0128 is effective against intrahepatic cholangiocarcinoma in mice. Journal of Hepatology, 2017, 67, 1194-1203.	3.7	77
14	Prognostic markers and putative therapeutic targets for hepatocellular carcinoma. Molecular Aspects of Medicine, 2010, 31, 179-193.	6.4	75
15	Altered methionine metabolism and global DNA methylation in liver cancer: Relationship with genomic instability and prognosis. International Journal of Cancer, 2007, 121, 2410-2420.	5.1	73
16	Role of transcriptional and posttranscriptional regulation of methionine adenosyltransferases in liver cancer progression. Hepatology, 2012, 56, 165-175.	7.3	73
17	<i>S</i>-adenosyl methionine regulates ubiquitin-conjugating enzyme 9 protein expression and sumoylation in murine liver and human cancers. Hepatology, 2012, 56, 982-993.	7.3	70
18	The mTORC2â€Akt1 Cascade Is Crucial for câ€Myc to Promote Hepatocarcinogenesis in Mice and Humans. Hepatology, 2019, 70, 1600-1613.	7.3	70

#	Article	IF	Citations
19	Genetic Alterations in Liver Carcinogenesis: Implications for New Preventive and Therapeutic Strategies. Critical Reviews in Oncogenesis, 2000, 11, 44.	0.4	65
20	Cell cycle deregulation in liver lesions of rats with and without genetic predisposition to hepatocarcinogenesis. Hepatology, 2002, 35, 1341-1350.	7.3	63
21	Down-regulation of c-myc and Cyclin D1 genes by antisense oligodeoxy nucleotides inhibits the expression of E2F1 and in vitro growth of HepG2 and Morris 5123 liver cancer cells. Carcinogenesis, 2003, 25, 333-341.	2.8	59
22	Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma. Clinical Cancer Research, 2019, 25, 403-413.	7.0	56
23	Aberrant iNOS signaling is under genetic control in rodent liver cancer and potentially prognostic for the human disease. Carcinogenesis, 2008, 29, 1639-1647.	2.8	54
24	Activation of v-Myb avian myeloblastosis viral oncogene homolog-like2 (MYBL2)-LIN9 complex contributes to human hepatocarcinogenesis and identifies a subset of hepatocellular carcinoma with mutant p53. Hepatology, 2011, 53, 1226-1236.	7.3	53
25	Laboratory test alterations in patients with COVID-19 and non COVID-19 interstitial pneumonia: a preliminary report. Journal of Infection in Developing Countries, 2020, 14, 685-690.	1.2	47
26	Genetic and Epigenetic Control of Molecular Alterations in Hepatocellular Carcinoma. Experimental Biology and Medicine, 2009, 234, 726-736.	2.4	46
27	Regulation of Amphiregulin Gene Expression by Î²-Catenin Signaling in Human Hepatocellular Carcinoma Cells: A Novel Crosstalk between FGF19 and the EGFR System. PLoS ONE, 2012, 7, e52711.	2.5	45
28	Dissection of Signal Transduction Pathways as a Tool for the Development of Targeted Therapies of Hepatocellular Carcinoma. Reviews on Recent Clinical Trials, 2007, 2, 217-236.	0.8	43
29	Multifocal hepatocellular carcinoma: intrahepatic metastasis or multicentric carcinogenesis?. Annals of Translational Medicine, 2015, 3, 4.	1.7	39
30	Rasâ€driven proliferation and apoptosis signaling during rat liver carcinogenesis is under genetic control. International Journal of Cancer, 2008, 123, 2057-2064.	5.1	38
31	Mybl2 expression is under genetic control and contributes to determine a hepatocellular carcinoma susceptible phenotype. Journal of Hepatology, 2011, 55, 111-119.	3.7	36
32	Correlation of c-myc overexpression and amplification with progression of preneoplastic liver lesions to malignancy in the poorly susceptible wistar rat strain. , 1999, 25, 21-29.		34
33	Inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase activity and gene expression by dehydrocpiandrosterone in preneoplastic liver nodules. Carcinogenesis, 1995, 16, 1537-1542.	2.8	31
34	An expression signature of phenotypic resistance to hepatocellular carcinoma identified by cross-species gene expression analysis. Cellular Oncology (Dordrecht), 2012, 35, 163-173.	4.4	30
35	c-myc amplification in pre-malignant and malignant lesions induced in rat liver by the resistant hepatocyte model. , 1996, 68, 136-142.		29
36	Alterations of Methionine Metabolism as Potential Targets for the Prevention and Therapy of Hepatocellular Carcinoma. Medicina (Lithuania), 2019, 55, 296.	2.0	29

#	Article	IF	Citations
37	Chemopreventive N-(4-hydroxyphenyl)retinamide (fenretinide) targets deregulated NF-ÂB and Mat1A genes in the early stages of rat liver carcinogenesis. Carcinogenesis, 2004, 26, 417-427.	2.8	28
38	SHORT COMMUNICATION: The BN rat strain carries dominant hepatocarcinogen resistance loci. Carcinogenesis, 1996, 17, 1765-1768.	2.8	27
39	Deregulation of signalling pathways in prognostic subtypes of hepatocellular carcinoma: Novel insights from interspecies comparison. Biochimica Et Biophysica Acta: Reviews on Cancer, 2012, 1826, 215-237.	7.4	27
40	Alterations of ornithine decarboxylase gene during the progression of rat liver carcinogenesis. Carcinogenesis, 1993, 14, 1077-1080.	2.8	26
41	Polygenic control of hepatocarcinogenesis in Copenhagen Ã— F344 rats. International Journal of Cancer, 2004, 111, 9-16.	5.1	26
42	DNA-PKcs: A promising therapeutic target in human hepatocellular carcinoma?. DNA Repair, 2016, 47, 12-20.	2.8	25
43	TEA Domain Transcription Factor 4 Is the Major Mediator of Yes-Associated Protein Oncogenic Activity in Mouse and Human Hepatoblastoma. American Journal of Pathology, 2019, 189, 1077-1090.	3.8	25
44	Persistent chemopreventive effect of S-adenosyl-L-methionine on the development of liver puptative preneoplastic lesions induced by thiobenzamide in diethylnitrosamine-initiated rats. Carcinogenesis, 1996, 17, 1533-1537.	2.8	24
45	Inhibition of HSF1 suppresses the growth of hepatocarcinoma cell lines <i>in vitro</i> and AKT-driven hepatocarcinogenesis in mice. Oncotarget, 2017, 8, 54149-54159.	1.8	24
46	Deregulation of methionine metabolism as determinant of progression and prognosis of hepatocellular carcinoma. Translational Gastroenterology and Hepatology, 2018, 3, 36-36.	3.0	23
47	Transferrin and transferrin receptor gene expression and iron uptake in hepatocellular carcinoma in the rat. Hepatology, 1998, 27, 452-461.	7.3	22
48	Post-translational deregulation of YAP1 is genetically controlled in rat liver cancer and determines the fate and stem-like behavior of the human disease. Oncotarget, 2016, 7, 49194-49216.	1.8	20
49	The degradation of cell cycle regulators by SKP2/CKS1 ubiquitin ligase is genetically controlled in rodent liver cancer and contributes to determine the susceptibility to the disease. International Journal of Cancer, 2010, 126, 1275-1281.	5.1	19
50	Frequent loss of heterozygosity at the Hcr1 (hepatocarcinogenesis resistance) locus on chromosome 10 in primary hepatocellular carcinomas from LFF1 rat strain. Hepatology, 2001, 33, 1110-1117.	7.3	18
51	MicroRNA-203 impacts on the growth, aggressiveness and prognosis of hepatocellular carcinoma by targeting <i>MAT2A</i> and <i>MAT2B</i> genes. Oncotarget, 2019, 10, 2835-2854.	1.8	18
52	S-Adenosylmethionine: From the Discovery of Its Inhibition of Tumorigenesis to Its Use as a Therapeutic Agent. Cells, 2022, 11, 409.	4.1	18
53	Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis. Oncotarget, 2017, 8, 90638-90650.	1.8	17
54	Functional role of SGK3 in PI3K/Pten driven liver tumor development. BMC Cancer, 2019, 19, 343.	2.6	17

#	Article	IF	Citations
55	Chromosome mapping of multiple loci affecting the genetic predisposition to rat liver carcinogenesis. Cancer Research, 2002, 62, 4459-63.	0.9	17
56	Phenotypic reversion of rat neoplastic liver nodules is under genetic control. International Journal of Cancer, 2003, 105, 70-75.	5.1	16
57	Genetic control of resistance to hepatocarcinogenesis by the mouseHpcr3locus. Hepatology, 2008, 48, 617-623.	7.3	16
58	Alterations of methionine metabolism in hepatocarcinogenesis: the emergent role of glycine N-methyltransferase in liver injury. Annals of Gastroenterology, 2018, 31, 552-560.	0.6	15
59	Experimental Models to Define the Genetic Predisposition to Liver Cancer. Cancers, 2019, 11, 1450.	3.7	15
60	Oncogene-dependent addiction to carbohydrate-responsive element binding protein in hepatocellular carcinoma. Cell Cycle, 2018, 17, 1496-1512.	2.6	14
61	Post-translational inhibition of YAP oncogene expression by 4-hydroxynonenal in bladder cancer cells. Free Radical Biology and Medicine, 2019, 141, 205-219.	2.9	13
62	Implication of Bcl-2 family genes in basal and d-amphetamineâ€“induced apoptosis in preneoplastic and neoplastic rat liver lesions. Hepatology, 2000, 31, 956-965.	7.3	12
63	SNAI1 Promotes the Cholangiocellular Phenotype, but not Epithelialâ€“Mesenchymal Transition, in a Murine Hepatocellular Carcinoma Model. Cancer Research, 2019, 79, 5563-5574.	0.9	12
64	Interaction of major genes predisposing to hepatocellular carcinoma with genes encoding signal transduction pathways influences tumor phenotype and prognosis. World Journal of Gastroenterology, 2008, 14, 6601.	3.3	12
65	Focal adhesion kinase activation limits efficacy of Dasatinib in câ€Myc driven hepatocellular carcinoma. Cancer Medicine, 2018, 7, 6170-6181.	2.8	11
66	Mapping a Sex Hormoneâ€“Sensitive Gene Determining Female Resistance to Liver Carcinogenesis in a Congenic F344.BN-Hcs4 Rat. Cancer Research, 2006, 66, 10384-10390.	0.9	10
67	Identification and chromosome mapping of loci predisposing to colorectal cancer that control Wnt/Î²-catenin pathway and progression of early lesions in the rat. Carcinogenesis, 2007, 28, 2367-2374.	2.8	10
68	Blood Cell Count Indexes of Systemic Inflammation in Carotid Artery Disease: Current Evidence and Future Perspectives. Current Pharmaceutical Design, 2021, 27, 2170-2179.	1.9	9
69	HCC in the Era of Direct-Acting Antiviral Agents (DAAs): Surgical and Other Curative or Palliative Strategies in the Elderly. Cancers, 2021, 13, 3025.	3.7	6
70	Focal loss of long non-coding RNA-PRAL, as determinant of cell function and phenotype of hepatocellular carcinoma. Annals of Translational Medicine, 2016, 4, 183-183.	1.7	5
71	An infernal crossâ€talk between oncogenic Î²â€catenin and câ€Met in hepatocellular carcinoma: Evidence from mouse modeling. Hepatology, 2016, 64, 1421-1423.	7.3	5
72	New insights on the role of epigenetic alterations in hepatocellular carcinoma. Journal of Hepatocellular Carcinoma, 2014, 1, 65.	3.7	4

#	Article	IF	Citations
73	Nuclear localization dictates hepatocarcinogenesis suppression by glycine N-methyltransferase. Translational Oncology, 2022, 15, 101239.	3.7	4
74	Sulfatase 1: a new Jekyll and Hyde in hepatocellular carcinoma?. Translational Gastroenterology and Hepatology, 2016, 1, 43-43.	3.0	3
75	The complex role of bone morphogenetic protein 9 in liver damage and regeneration: New evidence from in vivo and in vitro studies. Liver International, 2018, 38, 1547-1549.	3.9	2
76	Epidermal growth factor-like repeats and discoidin I-like domains 3: a multifaceted oncoprotein at the crossroad of MAPK and TGF-beta pathways in human hepatocellular carcinoma. Translational Cancer Research, 2016, 5, 103-109.	1.0	2
77	Phenotype: the result of a complex and still largely unknown interplay between molecules. Translational Cancer Research, 2016, 5, S895-S897.	1.0	0